Does repeated annual influenza vaccination increase risk of contracting influenza?
No—continue annual influenza vaccination; current top-tier guidelines recommend yearly vaccination for everyone ≥6 months because it reduces serious outcomes (hospitalization, death) and overall disease burden, and they do not find that repeat annual vaccination increases influenza risk. 1, 2
Guideline anchor (mortality/morbidity/QOL prioritized)
- ACIP 2025–26 and 2024–25: strong, consistent recommendation for routine annual influenza vaccination for all persons ≥6 months without contraindication; no recommendation to skip or stagger years due to “repeat vaccination” concerns. This reflects net benefit in preventing severe disease and death across seasons and age groups 1, 2.
- Pediatric and global guidance similarly endorse annual vaccination to reduce severe outcomes; no guidance suggests increased infection risk from repeated annual dosing that would alter practice 3, 4.
What the research shows (nuance, but does not overturn practice)
- Some observational seasons show modestly lower vaccine effectiveness for A(H3N2) among repeat vaccinees, even after accounting for earlier vaccination and within-season waning (e.g., OR≈1.11 for H3N2 positivity), but effects are small, subtype/season-specific, and do not consistently translate into higher severe outcomes; these data are not sufficient to change recommendations 5.
- UK cohort: potential reduction in relative VE in ≥65 years in some seasons, but residual confounding limits inference; no clear signal of increased influenza incidence that warrants avoiding annual vaccination 6.
- Older meta-analyses/reviews note heterogeneity and possible reduced effectiveness with LAIV or under antigenic mismatch, especially for H3N2, but evidence is inconsistent and largely in children or specific vaccine types; adult data are limited and do not demonstrate increased clinical risk that outweighs benefits of annual vaccination 7, 8.
- Modeling or mechanistic/opinion pieces (e.g., “borrow now, pay later,” immunologic hypotheses) are not patient-outcome trials and should not guide practice over contemporary guidelines 9, 10.
Practical algorithm (what to do now)
- Everyone ≥6 months: vaccinate annually with an age-appropriate influenza vaccine; for adults ≥65, prefer high-dose, adjuvanted IIV, or recombinant options when available to maximize protection against severe outcomes 2.
- Do not skip vaccination due to prior-year vaccination history; timing: vaccinate before local season onset; if vaccinated early, seniors may still benefit most from high-dose/adjuvanted formulations given waning concerns 1, 2.
- High-risk patients (pregnant, young children, elderly, chronic diseases, immunocompromised): prioritize vaccination annually; consider early antiviral treatment if infected/exposed to further reduce hospitalization/death risk 4.
Pitfalls and caveats
- Avoid over-interpreting small, subtype-specific VE fluctuations as increased disease risk from repeat vaccination; these do not outweigh mortality/morbidity benefits shown in population data and reflected in ACIP guidance 1, 2.
- Use recommended formulations and correct timing; suboptimal match or very early vaccination can modestly affect VE, but the remedy is not skipping years—it's choosing appropriate vaccine types and timely administration 2.
- LAIV-specific concerns in prior analyses under mismatch: consider IIV or recombinant options when efficacy is a concern 7, 2.